Stepping in to provide injectable drugs that are in short supply in the US is paying off for Hikma Pharmaceuticals in terms of stronger and deeper relationships with hospitals and their group purchasing organizations, the group’s CEO Siggi Olafsson told Generics Bulletin during an exclusive interview.
“Our relationship with the customers, the hospitals, has been significantly strengthened by being able to step into a shortage situation,”...




